Pfizer is to provide its Ibrance ( palbociclib ) breast cancer drug , viewed as one of the most important in preventing the disease , free of charge to NHS patients whilst it awaits a final decision on cost effectiveness by the UK 's National Institute For Health and Family Excellence ( NICE ) . NICE approved the drug , which cost £ 79,650 ( $ 2020 ) for a full course , in draft guidance in February . Approximately 6,000 UK patients will be eligible for the treatment .
Pfizer is to provide its Ibrance (palbociclib) breast cancer drug, viewed as one of the most important in treating the disease, free of charge to NHS patients whilst it awaits a final decision on cost effectiveness by the UK's National Institute For Health and Clinical Excellence (NICE). NICE rejected the drug, which costs £79,650 ($103,000) for a full course, in draft guidance in February. Approximately 6,000 UK patients could be eligible for the treatment.